Giorgia Scarpellino

Dr. Giorgia Scarpellino

Department of Biology and Biotechnology, University of Pavia, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
EZEstella Zuccolo
Estella Zuccolo
Umberto LaforenzaUmberto Laforenza
Umberto Laforenza
SNSharon Negri
Sharon Negri
LBLaura Botta
Laura Botta
Roberto Berra-RomaniRoberto Berra-Romani
Roberto Berra-Romani
Francesco MocciaFrancesco Moccia
Francesco Moccia

19 November 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
EZEstella Zuccolo
Estella Zuccolo
DKDlzar A. Kheder
Dlzar A. Kheder
DLDmitry Lim
Dmitry Lim
APAngelica Perna
Angelica Perna
FNFrancesca Di Nezza
Francesca Di Nezza
Francesco MocciaFrancesco Moccia
Francesco Moccia

24 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
EZEstella Zuccolo
Estella Zuccolo
Umberto LaforenzaUmberto Laforenza
Umberto Laforenza
FFFederica Ferulli
Federica Ferulli
GPGiorgia Pellavio
Giorgia Pellavio
Giorgia ScarpellinoGiorgia Scarpellino
Giorgia Scarpellino
Francesco MocciaFrancesco Moccia
Francesco Moccia
Stim and Orai mediate constitutive Ca2+ entry and control endoplasmic reticulum Ca2+ refilling in primary cultures of colorectal carcinoma cells Stim and Orai mediate constitutive Ca2+ entry and control endoplasmic reticulum Ca2+ refilling in primary cultures of colorectal carcinoma cells

1 January 2018 in Stem Cells and Development
Verified
Journal Article
Closed access
EZEstella Zuccolo
Estella Zuccolo
CBChristian Di Buduo
Christian Di Buduo
FLFrancesco Lodola
Francesco Lodola
SOstefania orecchioni
stefania orecchioni
Giorgia ScarpellinoGiorgia Scarpellino
Giorgia Scarpellino
Francesco MocciaFrancesco Moccia
Francesco Moccia
Stromal cell-derived factor-1α (SDF-1α) drives endothelial colony-forming cell (ECFC) homing and incorporation within neovessels, thereby restoring tissue perfusion in ischemic tissues and favoring tumor vascularization and metastasis. SDF-1α stimulates ECFC migration by activating the Gi-protein-coupled receptor, CXCR4, and then engaging the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway. Sporadic evidence showed that SDF-1α may also act through an increase in intracellular Ca2+ concentration ([Ca2+]i) in bone marrow-derived hematopoietic progenitor cells and fully differentiated endothelial cells. Of note, recent evidence demonstrated that intracellular Ca2+ signals play a key role in controlling the proangiogenic activity of ECFCs. The present investigation was, therefore, undertaken to assess whether and how SDF-1α induces ECFC motility by triggering intracellular Ca2+ signals. We found that SDF-1α caused a dose-dependent increase in [Ca2+]i that was inhibited by ADM3100, a selective CXCR4 antagonist. Pharmacological manipulation revealed that the Ca2+ response to [Ca2+]i was shaped by an initial intracellular Ca2+ release through inositol-1,4,5-trisphosphate receptors (InsP3Rs), followed by a sustained phase of extracellular Ca2+ entry through store-operated Ca2+ channels. InsP3-dependent Ca2+ release and store-operated Ca2+ entry (SOCE) were both necessary for SDF-1α-induced extracellular signal-regulated kinases 1/2 (ERK 1/2) and AKT phosphorylation. Finally, SDF-1α employed intracellular Ca2+ signals, ERK 1/2, and PI3K/AKT to promote ECFC migration in vitro and neovessel formation in vivo. These data, therefore, provide the first evidence that SDF-1α induces ECFC migration through the Ca2+-dependent activation of the ERK 1/2 and PI3K/AKT pathways.

Verified
Journal Article
Open access
PDF file
Francesco MocciaFrancesco Moccia
Francesco Moccia
VBValentina Brunetti
Valentina Brunetti
TSTeresa Soda
Teresa Soda
Roberto Berra-RomaniRoberto Berra-Romani
Roberto Berra-Romani
Giorgia ScarpellinoGiorgia Scarpellino
Giorgia Scarpellino
A monolayer of endothelial cells lines the innermost surface of all blood vessels, thereby coming into close contact with every region of the body and perceiving signals deriving from both the bloodstream and parenchymal tissues. An increase in intracellular Ca2+ concentration ([Ca2+]i) is the main mechanism whereby vascular endothelial cells integrate the information conveyed by local and circulating cues. Herein, we describe the dynamics and spatial distribution of endothelial Ca2+ signals to understand how an array of spatially restricted (at both the subcellular and cellular levels) Ca2+ signals is exploited by the vascular intima to fulfill this complex task. We then illustrate how local endothelial Ca2+ signals affect the most appropriate vascular function and are integrated to transmit this information to more distant sites to maintain cardiovascular homeostasis. Vasorelaxation and sprouting angiogenesis were selected as an example of functions that are finely tuned by the variable spatio-temporal profile endothelial Ca2+ signals. We further highlighted how distinct Ca2+ signatures regulate the different phases of vasculogenesis, i.e., proliferation and migration, in circulating endothelial precursors.

13 March 2019 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Open access
PDF file
Giorgia ScarpellinoGiorgia Scarpellino
Giorgia Scarpellino
TGTullio Genova
Tullio Genova
LMLuca Munaron
Luca Munaron
Background: Purinergic signalling is involved in several physiological and pathophysiological processes. P2X7 Receptor (P2X7R) is a calcium-permeable ion channel that is gaining interest as a potential therapeutic target for the treatment of different diseases including inflammation, pain, psychiatric disorders and cancer. P2X7R is ubiquitously expressed and sensitive to high ATP levels, usually found in tumor microenvironment. P2X7R regulates several cell functions, from migration to cell death, but its selective contribution to tumor progression remains controversial.Objective: Current review was conducted to check involvement of P2X7R use in cancer treatment.Methods: We review the most recent patents focused on the use of P2X7R in the treatment of cancer.Results: P2X7R is an intriguing purinergic receptor that plays different roles in tumor progression.Conclusion: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies.